MMP9 is a potential AD biomarker for disease progression, with higher serum levels of MMP9 correlated with faster cognitive decline in patients with mild cognitive impairment attributed to AD (Abe et al., 2020). This evidence concerns the gene MMP9 and Alzheimer disease.